Page 338 - Read Online

Shrestha et al. Hepatoma Res 2019;5:32 I http://dx.doi.org/10.20517/2394-5079.2019.24 Page 15 of 17

46. Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res 2018;37:110.
47. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, et al. Programmed death ligand 1 expression in hepatocellular
carcinoma: Relationship With clinical and pathological features. Hepatology 2016;64:2038-46.
48. Chang H, Jung W, Kim A, Kim HK, Kim WB, et al. Expression and prognostic significance of programmed death protein 1 and
programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. APMIS 2017;125:690-8.
49. Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, et al. PD-L1, Galectin-9 and CD8. Oncoimmunology 2017;6:e1273309.
50. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is
mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009;69:8067-75.
51. Wainberg ZA, Segal NH, Jaeger D, Lee K-H, Marshall J, et al. Safety and clinical activity of durvalumab monotherapy in patients with
hepatocellular carcinoma (HCC). J Clin Oncol 2017;35:4071.
52. Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48:622-34.
53. Cella D, Grünwald V, Escudier B, Hammers HJ, George S, et al. Patient-reported outcomes of patients with advanced renal cell
carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol
2019;20:297-310.
54. Jain S, Clark JI. Ipilimumab for the treatment of melanoma. Melanoma Manag 2015;2:33-9.
55. Kelley RK, Abou-Alfa GK, Bendell JC, Kim T-Y, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with
unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol 2017;35:4073.
56. Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, et al. A randomized, multicenter phase 3 study of durvalumab (D) and
tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin
Oncol 2018;36:TPS4144.
57. Finn RS, Ducreux M, Qin S, Galle PR, Zhu AX, et al. IMbrave150: A randomized phase III study of 1L atezolizumab plus
bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2018;36:TPS4141.
58. J Pishvaian M, S Lee M, Ryoo BY, Stein S, Lee KH, et al. LBA26Updated safety and clinical activity results from a phase Ib study of
atezolizumab + bevacizumab in hepatocellular carcinoma (HCC); Ann Oncol 2018;29; DOI:10.1093/annonc/mdy424.028.
59. Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in
patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36:4076.
60. Xue JM, Astère M, Zhong MX, Lin H, Shen J, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular
carcinoma and non-small cell lung cancer: a meta-analysis. Onco Targets Ther 2018;11:6119-28.
61. Deng L, Liang H, Burnette B, Beckett M, Darga T, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor
immunity in mice. J Clin Invest 2014;124:687-95.
62. Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary
Liver Tumors. J Oncol 2019;2019:4304817.
63. Harding JJ, Erinjeri JP, Tan BR, Reiss KA, Mody K, et al. A multicenter pilot study of nivolumab (NIVO) with drug eluting bead
transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC). J Clin Oncol
2018;36:TPS4146.
64. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
65. Chang EWY, Tai DW-M, Koo S-L, Ng MC, Yeong JPS, et al. A phase II open-label, single-centre, non-randomized trial of Y90
transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma:
An immunological study of radioembolization in combination with anti-PD1 therapy in HCC. J Clin Oncol 2018;36:TPS542.
66. Hecht JR, Prat A, Pless M, Cubillo A, Calvo A, et al. A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene
laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro)
(MASTERKEY-318). J Clin Oncol 2018;36:TPS3105.
67. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer 2018;118:9-16.
68. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, et al. Fulminant Myocarditis with Combination Immune Checkpoint
Blockade. N Engl J Med 2016;375:1749-55.
69. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis
2018;10:S480-S9.
70. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, et al; Group SfIoCTMW. Managing toxicities associated with immune
checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management
Working Group. J Immunother Cancer 2017;5:95.
71. McLoughlin KC, Brown ZJ, Shukla Y, Shukla V. Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary
malignancies. Discov Med 2018;26:85-92.
72. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, et al. Adaptive resistance to therapeutic PD-1 blockade is associated
with upregulation of alternative immune checkpoints. Nat Commun 2016;7:10501.
73. Peng W, Chen JQ, Liu C, Malu S, Creasy C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer
Discov 2016;6:202-16.
74. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, et al. Gut microbiome modulates response to anti-PD-1
immunotherapy in melanoma patients. Science 2018;359:97-103.
75. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.